<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02406105</url>
  </required_header>
  <id_info>
    <org_study_id>FSRSPD-COI-03</org_study_id>
    <nct_id>NCT02406105</nct_id>
  </id_info>
  <brief_title>An Effectiveness and Toxicity of CyberKnife Based Radiosurgery for Parkinson Disease</brief_title>
  <official_title>An Evaluation of Effectiveness and Toxicity of CyberKnife Based Functional Radiosurgery for Parkinson Disease Patients Suffering From Tremor and Its Implementation in Poland</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maria Sklodowska-Curie Institute - Oncology Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maria Sklodowska-Curie Institute - Oncology Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical objective of the study is estimation of effectiveness and safety of Cyber Knife
      based functional radiosurgery for Parkinson disease patients suffering from tremor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Basic treatment patients with Parkinson's disease (PD - Parkinson's disease) or essential
      tremor (ET - essential tremor) is a pharmacotherapy. In the case of lack of its
      effectiveness, the gold standard procedure is deep brain stimulation (DBS). Despite the
      proven efficacy, still remains a group of patients not eligible for this treatment. in such
      cases, ablation within the deep structures of the brain (thalamotomy, subthalamotomy,
      pallidotomy) can be considered.

      Thermoablation and radiosurgery (SRS - Stereotactic radiosurgery) are used: SRS is prefered
      for patients who are not candidates for invasive procedures.

      27 patients will be enrolled in this study. All patients will be immobilized in thermoplastic
      masks and planned (RT) on the base of CT/MRI fusion.

      The initial total dose in the target volume (thalamic nuclei complex - VoP and VoA ) will be
      70 Gy given in one fraction. The dose will be escalated every 5 Gy and the treatment effect
      and possible side effects will be evaluated. Dose escalation will be finished at a dose at
      which the effect of treatment will be satisfactory, or if side effects are unacceptable. The
      highest dose tested dose will be 110 Gy. Three patients will be irradiated with particular
      doses and observed at least 3 moths; then study will be continued.

      Patients will be controlled 3, 6, 9, 12, 18 months after treatment completion and, next every
      each 6 months. Neurologic and neuropsychologic status, local effect (MRI ) and eventual
      toxicity will be checked during follow-up (FU).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tremor reduction evaluated using Unified Parkinson's Disease Rating Scale</measure>
    <time_frame>1 year</time_frame>
    <description>Tremor reduction will be evaluated using Unified Parkinson's Disease Rating Scale (UDPRS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of treatment (evaluated using RTOG/EORTC Acute Radiation Morbidity Scoring Criteria and Late Radiation Morbidity Scoring Schema)</measure>
    <time_frame>1 year</time_frame>
    <description>Safety of treatment will be evaluated using RTOG/EORTC Acute Radiation Morbidity Scoring Criteria and Late Radiation Morbidity Scoring Schema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the value of magnetic resonance spectroscopy as a tool for metabolites proportions changes after PD radiosurgery (spectra of metabolites in irradiated volume)</measure>
    <time_frame>2 years</time_frame>
    <description>None grading system of serial spectroscopy dedicated for such purpose exists. We will check spectra of metabolites in irradiated volume and proportions between them, trying to form conclusions considering necrosis/gliosis forming.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implementation of CyberKnife radiosurgery for Parkinson disease patients not eligible for other treatment modality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Radiosurgical thalamotomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyber Knife based functional radiosurgical thalamotomy, photons 6MV, single dose 70-110 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiosurgical thalamotomy</intervention_name>
    <description>Cybernetic microradiosurgery based thalamotomy</description>
    <arm_group_label>Radiosurgical thalamotomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CyberKnife</intervention_name>
    <arm_group_label>Radiosurgical thalamotomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopatic Parkinson Disease (PD)

          -  Lack of effective pharmacotherapy

          -  Lack of possibilities of qualifications to DBS (deep brain stimulation) procedure

          -  Informed consent for participation in the study and for radiotherapy

        Exclusion Criteria:

          -  Age under 18

          -  Pregnancy

          -  Other than PD induced tremor

          -  Dementia, psychosis.

          -  Poor performance status

          -  Atrophic cerebral changes, structural changes in basal nuclei

          -  Lack of informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leszek Miszczyk, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leszek Miszczyk, MD, PhD</last_name>
    <phone>0048322788001</phone>
    <email>leszek@io.gliwice.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology Gliwice Branch</name>
      <address>
        <city>Gliwice</city>
        <state>Wybrzeze AK 15</state>
        <zip>44-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leszek Miszczyk, MD. PhD</last_name>
      <phone>+48322788001</phone>
      <email>leszek@io.gliwice.pl</email>
    </contact>
    <investigator>
      <last_name>Leszek Miszczyk, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grzegorz Wozniak, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agata Roch-Zniszczol, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dawid Larysz, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lukasz Zarudzki, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Malgorzata Fudzinska</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agnieszka Rozek</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Hooper AK, Okun MS, Foote KD, Fernandez HH, Jacobson C, Zeilman P, Romrell J, Rodriguez RL. Clinical cases where lesion therapy was chosen over deep brain stimulation. Stereotact Funct Neurosurg. 2008;86(3):147-52. doi: 10.1159/000120426. Epub 2008 Mar 12. Review.</citation>
    <PMID>18334856</PMID>
  </reference>
  <reference>
    <citation>Niranjan A, Jawahar A, Kondziolka D, Lunsford LD. A comparison of surgical approaches for the management of tremor: radiofrequency thalamotomy, gamma knife thalamotomy and thalamic stimulation. Stereotact Funct Neurosurg. 1999;72(2-4):178-84.</citation>
    <PMID>10853075</PMID>
  </reference>
  <reference>
    <citation>Young RF, Shumway-Cook A, Vermeulen SS, Grimm P, Blasko J, Posewitz A, Burkhart WA, Goiney RC. Gamma knife radiosurgery as a lesioning technique in movement disorder surgery. J Neurosurg. 1998 Aug;89(2):183-93.</citation>
    <PMID>9688111</PMID>
  </reference>
  <reference>
    <citation>Stancanello J, Romanelli P, Pantelis E, Sebastiano F, Modugno N. Atlas-based functional radiosurgery: early results. Med Phys. 2009 Feb;36(2):457-63.</citation>
    <PMID>19291984</PMID>
  </reference>
  <reference>
    <citation>LEKSELL L. The stereotaxic method and radiosurgery of the brain. Acta Chir Scand. 1951 Dec 13;102(4):316-9.</citation>
    <PMID>14914373</PMID>
  </reference>
  <reference>
    <citation>Lindquist C, Kihlström L, Hellstrand E. Functional neurosurgery--a future for the gamma knife? Stereotact Funct Neurosurg. 1991;57(1-2):72-81.</citation>
    <PMID>1725560</PMID>
  </reference>
  <reference>
    <citation>Young RF, Vermeulen S, Posewitz A, Shumway-Cook A. Pallidotomy with the gamma knife: a positive experience. Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:218-28.</citation>
    <PMID>9782254</PMID>
  </reference>
  <reference>
    <citation>Duma CM, Jacques DB, Kopyov OV, Mark RJ, Copcutt B, Farokhi HK. Gamma knife radiosurgery for thalamotomy in parkinsonian tremor: a five-year experience. J Neurosurg. 1998 Jun;88(6):1044-9.</citation>
    <PMID>9609299</PMID>
  </reference>
  <reference>
    <citation>Young RF, Jacques S, Mark R, Kopyov O, Copcutt B, Posewitz A, Li F. Gamma knife thalamotomy for treatment of tremor: long-term results. J Neurosurg. 2000 Dec;93 Suppl 3:128-35.</citation>
    <PMID>11143229</PMID>
  </reference>
  <reference>
    <citation>Niranjan A, Kondziolka D, Baser S, Heyman R, Lunsford LD. Functional outcomes after gamma knife thalamotomy for essential tremor and MS-related tremor. Neurology. 2000 Aug 8;55(3):443-6.</citation>
    <PMID>10932286</PMID>
  </reference>
  <reference>
    <citation>Okun MS, Stover NP, Subramanian T, Gearing M, Wainer BH, Holder CA, Watts RL, Juncos JL, Freeman A, Evatt ML, Schuele SU, Vitek JL, DeLong MR. Complications of gamma knife surgery for Parkinson disease. Arch Neurol. 2001 Dec;58(12):1995-2002.</citation>
    <PMID>11735773</PMID>
  </reference>
  <reference>
    <citation>Friehs GM, Park MC, Goldman MA, Zerris VA, Norén G, Sampath P. Stereotactic radiosurgery for functional disorders. Neurosurg Focus. 2007;23(6):E3. Review.</citation>
    <PMID>18081480</PMID>
  </reference>
  <reference>
    <citation>Duma CM. Movement disorder radiosurgery--planning, physics and complication avoidance. Prog Neurol Surg. 2007;20:249-66.</citation>
    <PMID>17317994</PMID>
  </reference>
  <reference>
    <citation>Kondziolka D, Ong JG, Lee JY, Moore RY, Flickinger JC, Lunsford LD. Gamma Knife thalamotomy for essential tremor. J Neurosurg. 2008 Jan;108(1):111-7. doi: 10.3171/JNS/2008/108/01/0111. Erratum in: J Neurosurg. 2008 Mar;108(3):635.</citation>
    <PMID>18173319</PMID>
  </reference>
  <reference>
    <citation>Young RF, Li F, Vermeulen S, Meier R. Gamma Knife thalamotomy for treatment of essential tremor: long-term results. J Neurosurg. 2010 Jun;112(6):1311-7. doi: 10.3171/2009.10.JNS09332.</citation>
    <PMID>19895197</PMID>
  </reference>
  <reference>
    <citation>Ohye C, Higuchi Y, Shibazaki T, Hashimoto T, Koyama T, Hirai T, Matsuda S, Serizawa T, Hori T, Hayashi M, Ochiai T, Samura H, Yamashiro K. Gamma knife thalamotomy for Parkinson disease and essential tremor: a prospective multicenter study. Neurosurgery. 2012 Mar;70(3):526-35; discussion 535-6. doi: 10.1227/NEU.0b013e3182350893.</citation>
    <PMID>21904267</PMID>
  </reference>
  <reference>
    <citation>Lim SY, Hodaie M, Fallis M, Poon YY, Mazzella F, Moro E. Gamma knife thalamotomy for disabling tremor: a blinded evaluation. Arch Neurol. 2010 May;67(5):584-8. doi: 10.1001/archneurol.2010.69.</citation>
    <PMID>20457958</PMID>
  </reference>
  <reference>
    <citation>Franzini A, Marchetti M, Brait L, Milanesi I, Messina G, Forapani E, Broggi G, Fariselli L. Deep brain stimulation and frameless stereotactic radiosurgery in the treatment of bilateral parkinsonian tremor: target selection and case report of two patients. Acta Neurochir (Wien). 2011 May;153(5):1069-75. doi: 10.1007/s00701-011-0962-0. Epub 2011 Feb 20.</citation>
    <PMID>21336920</PMID>
  </reference>
  <reference>
    <citation>Yu C, Main W, Taylor D, Kuduvalli G, Apuzzo ML, Adler JR Jr. An anthropomorphic phantom study of the accuracy of Cyberknife spinal radiosurgery. Neurosurgery. 2004 Nov;55(5):1138-49.</citation>
    <PMID>15509320</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2015</study_first_submitted>
  <study_first_submitted_qc>April 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2015</study_first_posted>
  <last_update_submitted>April 1, 2015</last_update_submitted>
  <last_update_submitted_qc>April 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tremor</keyword>
  <keyword>Parkinson disease</keyword>
  <keyword>functional radioablation</keyword>
  <keyword>Cyber Knife radiosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

